HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Mexico Deals OTC Drugs

Hypera Immediately Offloads Takeda Brands To Concentrate On Brazil

  • News

Executive Summary

Hypera is offloading a basket of brands it recently acquired from Takeda which are sold primarily in Mexico to São Paulo-based Eurofarma. 

You may also be interested in...



Hypera Strikes Takeda Deal To Dominate Brazil's OTC Market

Brazil's Hypera is paying Takeda $0.8bn for a portfolio of brands which will make it the "undisputed leader" in the South American country's OTC market. 

Hypera Buys Boehringer’s Buscopan in Brazil

Hypera has agreed to pay BRL1.3bn to acquire the rights in Brazil to Buscopan and Buscofem from Boehringer Ingelheim. 

India Eases Paracetamol Export Restrictions

Global supply of paracetamol could soon improve after India said it would allow some exports of the drug. The country introduced severe export restrictions in March to ensure it had a sufficient stockpile of paracetamol to meet internal demand during the COVID-19 outbreak.

Table

View full table

Topics

Related Companies

Tags:
Mexico Deals OTC Drugs
UsernamePublicRestriction

Register

RS149824

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By